Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2016 1
2017 1
2018 2
2019 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Surgical Repair of Occult Inguinal Hernia?
Kaplan AJ, Hinks RP, Bailey DW, Cleveland E, Berry JS. Kaplan AJ, et al. Among authors: berry js. J Am Coll Surg. 2019 May;228(5):808-809. doi: 10.1016/j.jamcollsurg.2019.01.006. Epub 2019 Feb 13. J Am Coll Surg. 2019. PMID: 30770319 No abstract available.
Venous thromboembolism during combat operations: a 10-y review.
Hutchison TN, Krueger CA, Berry JS, Aden JK, Cohn SM, White CE. Hutchison TN, et al. Among authors: berry js. J Surg Res. 2014 Apr;187(2):625-30. doi: 10.1016/j.jss.2013.11.008. Epub 2013 Nov 15. J Surg Res. 2014. PMID: 24405609
Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EA. Vreeland TJ, et al. Among authors: berry js. Clin Immunol. 2018 Jul;192:6-13. doi: 10.1016/j.clim.2018.03.010. Epub 2018 Mar 21. Clin Immunol. 2018. PMID: 29574039 Free PMC article. Clinical Trial.
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
Brown TA, Byrd K, Vreeland TJ, Clifton GT, Jackson DO, Hale DF, Herbert GS, Myers JW, Greene JM, Berry JS, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwel GL, Peoples GE. Brown TA, et al. Among authors: berry js. Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5. Cancer Med. 2019. PMID: 31274231 Free PMC article. Clinical Trial.
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors.
Herbert GS, Vreeland TJ, Clifton GT, Greene JM, Jackson DO, Hardin MO, Hale DF, Berry JS, Nichol P, Yin S, Yu X, Wagner TE, Peoples GE. Herbert GS, et al. Among authors: berry js. Vaccine. 2018 May 31;36(23):3247-3253. doi: 10.1016/j.vaccine.2018.04.078. Epub 2018 May 1. Vaccine. 2018. PMID: 29724512 Clinical Trial.
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE. Jackson DO, et al. Among authors: berry js. Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305. Oncotarget. 2017. PMID: 27852036 Free PMC article. Clinical Trial.